Vectura Share Discussion Threads

[a1ord53] 06/10/2020 09:13

Thanks Taffy 100.

Bottom line - today at 10 am ET show goes on episode # 2 !
3 years litigations not enough ! Jurors verdict not good ! Judgement wrong ! Retrial ?!
You can do what ever you want, if you GSK and can spend shareholders money limitless ( of course money been stollen from VEC shareholders ) !

[taffy100] 06/10/2020 06:41

Vectura Limited v. GlaxoSmithKline LLC
Court of Appeals for the Federal Circuit
Date Argued: October 5th, 2020

[srpactive] 05/10/2020 12:52

b7

I also hold ncyt, vec will follow soon enough, mm's trying
to bore and panic investors into selling.

dyor

[justiceforthemany] 05/10/2020 12:16

So should be some developments on the GSK case today? The share price is certainly not pricing in the extra $200M that could come our way resulting in a cash position of $300M and potential for large returns.

[insideryou] 02/10/2020 16:35

Back to the trading range it would appear. 20%drop?

[polaris] 02/10/2020 15:35

...where do you think i put my buy orders? ;-) Sadly it was after lunchtime and i missed the channel bottom entry point while transferring cash to trading account...

[diesel] 02/10/2020 15:18

Well we are still within our long term trend channel, patience required...

[polaris] 02/10/2020 14:43

I have buy orders in but not triggered so far.

[pooroldboy55] 02/10/2020 14:28

All very good but is that enough for you to buy back in.
Cheers A

[a1ord53] 02/10/2020 13:56

Polaris, thanks for update.
Didnt understand how much funds estimated they will have at the year end ?
Thx

[polaris] 02/10/2020 13:37

Cash position
Cash and cash equivalents at end H1 £81.9 M. Since period end the tranche 2 buyback has taken about £7.1 M of that. Other post period changes in cash position are a $5 M milestone for Breezhaler and £3-5 M from CDMO agreements signed in H1 2020. So, without any cash generation in H2 the cash pile is already back around that at end H1.

Products launched in 2020
Enerzair(R) Breezhaler(R) (QVM149) will launch in Europe and Japan before year end (3 % royalty on sales)
Airbufo Forspiro (Symbicort analogue EU) launched (royalty on sales, can't remember about any manufacturing revenue)

Delayed
Generic Advair (VR315) with a minor CRL. I'd expect approval within 3-4 months on addressing and submitting a reply. That yields the $11 M milestone in H1 2021 and the mid-teens sales royalties to kick in from mid 2021. There will only be three market entrants as the fourth gave up after discussions with FDA post CRL. Advair market value still holding up pretty well so there is space for third entrant to make reasonable return.

Development
A whole host of small contracts - no-one can say right now whether any of these will lead to future royalties. However, without the development contracts then you have no hope of anything going forward.

VR2081 (generic Symbicort US) is progressing. I'd like to see that make some significant headway wrt setting a date for submission. It has trundled along for a long time now.

Generic Ellipta series. Only three of the 5 products will be commercially viable for a generic entrant. There needs to be a proper update on this within 12 months. I want timelines for submission!

GSK litigation
Still rolling along. It's the best part of $200 M with interest and extent of the royalty agreement expiry date. It's big money to VEC, less so to GSK. I'd be more worried about the generic Ellipta series if i was GSK - product line will be worth about $4 Bn to them by 2024...

Summary
VEC is changing. I am not yet convinced by the new direction and the lack of transparency cf. the previous organisation. This post only covers a few aspects of VEC. Flutiform remains the bulk of the value chain.

[alexchry] 02/10/2020 10:17

Have to agree, just hope market is wrong about court case and Advair otherwise the near future looks bleak.

[a1ord53] 02/10/2020 10:09

Market doesnt believe in Advair approval and win in court !

Shares of Vectura have no support and can falling and falling - painfully for shareholders.

Vectura king mistaked - no 150 or 200 p in sight.

No buy back either means management doesnt believe in current sp,growth and success !

Current business model didnt impress investors and myself as well.

Hope for take over( still 80mln £ in account and another 40-50 mln to come in 2d half) !

With current management no chances to create descent business and get descent divis. They will rather save their bottoms and pocket our money in their accounts with schemes and compensations plans.

[pooroldboy55] 02/10/2020 09:23

Just gone under 100p. Well Paul we could easily get back to the 80p range will you be buying back in ?
POB

[base7] 01/10/2020 23:04

Following on from my theme this morning,our Non Exec ,Juliet Thompson,is also a non exec of Novacyte-another super successful C-19 stock.Any chance of collaborating with either of them

[cockneytrader] 01/10/2020 18:44

For what's it worth, I believe we will get approval for Advair - very late in the day. And I believe we have a good chance in court. The share price drift was inevitable.

[a1ord53] 01/10/2020 17:13

Justice.... first arguments will take place on 5 th of October on telephone.So its nothing yet to leak.

“ 45 NOTICE OF TELEPHONIC ORAL ARGUMENT. Panel: 2010D. Case scheduled October 5, 2020. “

[alexchry] 01/10/2020 17:06

Advair generic approval early next year, been saying that for years, still may be six months away at best and even may be rejected again so no wonder share price is weak.

[justiceforthemany] 01/10/2020 16:40

Not sure what is going on here - news leaked of the appeal?
Is that even going on at the moment?
Meanwhile UT consistently knocks 1p off the closing price.
Still above 200 day MA and not selling any.
Market can play tricks.

[base7] 01/10/2020 09:26

Disappointing share price performance since Results ,which were positive & pity a new buy back program was not announced as we have a growing cash pile & little indication of any plans to invest it & another £10mill buy back @ 100-200 shares p day would have seen us through to the Advair approval .Perhaps we have a cunning plan to invest in an exciting new project?
On another point ,I don’t recollect whether Paul Fry’s appointment(earlier this year ) as a Non Exec Director of Avacta (a c-19 stock whose shares have multi bagged in a few months )has been discussed here & whether there maybe scope for any collaboration between us ?

[popper joe] 30/9/2020 13:25

I hope they didn't pay £1.37 for the extra share. Or perhaps it is a sign? :-)

[polaris] 30/9/2020 13:15

I'm angry. Totalled up the tranche 2 and they over bought back by 1 share! Total £10,000,001.36!! Sack the broker...LOL! ;-)Slow morning...